Novavax, CPLB And ICGEB Collaboration Honored For Malaria Vaccine Progress At Vaccine World Summit India 2013
ROCKVILLE, Md., March 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that its collaboration to develop a novel malaria vaccine in India has been honored by the Vaccine World Summit India 2013 conference for having the "Most Promising Vaccine for Emerging Diseases in India." This competitive award recognized the progress made by Novavax, Cadila Pharmaceuticals Ltd. Biologicals (CPLB) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a new and effective malaria vaccine. It was one of five inaugural awards honoring achievements in India's vaccine industry.
The Novavax/CPLB/ICGEB collaboration was established in 2012 to combine the advanced vaccine technology of Novavax with the malaria vaccine research capabilities of ICGEB and vaccine manufacturing capability of CPLB. The project is being funded by India's Department of Biotechnology Vaccine Grand Challenge Program and managed by the Malaria Vaccine Development Program, a New Delhi-based not-for-profit organization established to support the development of malaria vaccines.
"The technology from Novavax has allowed us to explore a novel delivery platform to develop malaria vaccines and the initial results from pre-clinical studies are exciting" said Professor Virander S. Chauhan, Director, ICGEB.
"We thank our industry peers for honoring this important work and congratulate our colleagues in India for their outstanding progress toward the development of an effective malaria vaccine," said Stanley C. Erck, President and CEO of Novavax. "Malaria remains a major public health problem in many parts of the tropical world and we are committed to identifying a safe and effective vaccine that can prevent its spread and devastating effects." About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com . About International Centre for Genetic Engineering and Biotechnology (ICGEB) ICGEB ( www.icgeb.org ) provides a scientific and educational environment of the highest standard and conducts innovative research in life sciences for the benefit of developing countries. With Components in Trieste, Italy, New Delhi, India and Cape Town, South Africa, the Centre forms an interactive network with Affiliated Centres in ICGEB Member States. The ICGEB New Delhi Component conducts basic and translational research on infectious diseases including malaria, tuberculosis, HIV, dengue, influenza, hepatitis E and hepatitis B as well as on agriculture related problems relevant to developing countries. About CPLB CPL Biologicals Pvt. Ltd., a joint-venture biotechnology company established by Novavax Inc. and Cadila Pharmaceuticals, one of the largest privately held pharmaceutical companies in India based in Ahmedabad, manufactures VLP influenza vaccines developed by Novavax. CPLB has a state-of-the-art manufacturing facility that is capable of producing a significant volume of novel vaccine doses every year. This facility utilizes the single-use vaccine bioprocessing system used by Novavax at its pilot plant in Rockville, Maryland.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
